Targets › 3CLPRO
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Jun 2028.
Open in Phaseline: the race on 3CLPRO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Paxlovid Combination of nirmatrelvir (SARS-CoV-2 protease inhibitor) and ritonavir (CYP3A4 inhibito | 3CLPRO | Phase 2 | Post-acute Sequelae of COVID-19 | Jun 2028 |
Post-acute Sequelae of COVID-19 (1)
small molecule (1)
Icahn School of Medicine at Mount Sinai (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.